Unicus Pharmaceuticals (Unicus) is a Product Development and Contract R&D facility serving the pharmaceutical, cosmetic (skin and hair care) and personal care sectors.
Unicus provides non-sterile topical and oral product development, optimization, and scale-up support services to industry clients. We can design and develop over-the-counter (OTC), cosmetic, homeopathic, and pharmaceutical products based on your own product development ideas and targeted product profile. We would love to work with start-up, medium, or large companies that are facing innovation challenges and working on new brands or optimizing their existing brands.
Our Services include:
Our 4,000-sq. ft. R&D laboratory facility is located in Myles Standish Industrial Park, Taunton, Massachusetts. We can formulate starting from scratch or reformulate/optimize your existing formula. We have formulation expertise in different dosage forms such as solutions, sprays, suspensions, creams, gels, ointments, and others for topical and/or oral applications. We bank on our reputation for novel and innovative product development capabilities. We can provide you services on idea generation, selection of raw materials, development and screening of prototypes, design of stability studies, evaluation of dosage forms, selection of lead formulation, and sourcing of packaging materials.
We can assist you with scale up and commercial manufacturing of batches for non-clinical, toxicology and clinical studies, preparation and review of documents for regulatory filings, and quality assurance. We can support you in identifying vendors, drafting/editing/reviewing technical documents, solving scale-up and manufacturing challenges when you need technical expertise.
Currently we are taking projects in the following areas: Non-sterile Personal Care, Skin Care, Nailcare, Hair Care, Body & Bath, Spa, Baby/Children care, Homeopathic and Natural/Herbal Skincare Cosmetic & OTC products.
We can help you with 510K medical devices, novel/innovative formulation technology development, and platform/proprietary technology development around your compound of interest.
